[{"ID":"12720_27_NCT03296930","TOPIC_YEAR":2021,"RESPONSE":"$}}%\n\nB","PROBA":0.9999875665},{"ID":"30672_65_NCT01883024","TOPIC_YEAR":2021,"RESPONSE":"$}}%> A: eligible  B: excluded  C: not relevant for clinical trial","PROBA":0.9781402864},{"ID":"12418_27_NCT00720434","TOPIC_YEAR":2021,"RESPONSE":"$}}%\n\nB: excluded","PROBA":0.9999956936},{"ID":"17032_36_NCT01491828","TOPIC_YEAR":2021,"RESPONSE":"$}}%E2%80%8B%20A%3A%20eligible%20B%3A%20excluded%20C%3A%20not%20relevant%20for%20clinical%20trial.","PROBA":0.9878395093},{"ID":"7100_15_NCT04821219","TOPIC_YEAR":2021,"RESPONSE":"$}}%\n\nBased on the patient's history of pancreatic adenocarcinoma and the inclusion criteria of the clinical trial, the patient is eligible for the study. The patient has undergone EUS with biopsy, which has confirmed the diagnosis of pancreatic adenocarcinoma at the head of the pancreas. This meets the inclusion criterion of a confirmed diagnosis of pancreatic adenocarcinoma. Additionally, the patient's history of coronary artery disease, mitral valve prolapse, atrial fibrillation, hyperlipemia, hypertension, chronic kidney disease, hypothyroidism, and anemia do not meet any of the exclusion criteria listed in the clinical trial. Therefore, the patient is eligible for the study.\n\nAnswer: A","PROBA":0.9954514007},{"ID":"8090_17_NCT04210791","TOPIC_YEAR":2021,"RESPONSE":"$}}%\n\nB: excluded","PROBA":0.9999993443},{"ID":"7091_15_NCT04730765","TOPIC_YEAR":2021,"RESPONSE":"# A: eligible\n# B: excluded\n# C: not relevant for clinical trial","PROBA":0.9999882181},{"ID":"10176_15_NCT02081625","TOPIC_YEAR":2022,"RESPONSE":"$}}%\n\nB: excluded. The patient is excluded from the clinical trial because they have participated in other pharmacological clinical trial that might recover dystrophin protein by the readthrough or the exon-skipping therapy.","PROBA":0.9831793099},{"ID":"12547_27_NCT01750515","TOPIC_YEAR":2021,"RESPONSE":"$}}%\n\nBased on the information provided, the patient is eligible for the clinical trial. The patient meets all the inclusion criteria, such as having chronic HCV infection, being over 18 years old, and being able to receive standard Peg interferon+ribavirin treatment. The patient does not have any of the exclusion criteria, such as psychiatric diagnosis, anemia of hematologic origin, diabetic patient with uncontrolled diabetes, congestive heart failure or arrhythmia, hepatocellular carcinoma, HIV infection, hepatitis B infection, or autoimmune liver disease or alcoholic liver disease. Therefore, the patient is eligible for the clinical trial. The correct answer is A: eligible.","PROBA":0.9964256846},{"ID":"8073_17_NCT03984721","TOPIC_YEAR":2021,"RESPONSE":"$}}%\n\nB: excluded. The patient has systemic amyloidosis, which is an inclusion criterion, but the clinical trial specifically excludes patients with systemic amyloidosis.","PROBA":0.9688095924}]
